BIOVIGILANT SYSTEMS, INC. – Trademark Portfolio
Entity Type: 03
BIOVIGILANT SYSTEMS, INC. holds 13 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 9 (Computers & Electronics) — 13 filings in this category. The portfolio also extends into Class 41 (Education & Entertainment) across 2 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include IMD-A, BIOVIGILANT, and PHARMAMASTER. The owner is based in Tucson, AZ.
2015 W. Ruthrauff Road, Suite 153
Tucson, AZ 85705
Showing of trademarks Trademarks
Trademark Classifications
BIOVIGILANT SYSTEMS, INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Education; providing of training; entertainment; sporting and cultural activities
Frequently Asked Questions
How many trademarks does BIOVIGILANT SYSTEMS, INC. have?
BIOVIGILANT SYSTEMS, INC. has 13 U.S. trademarks filed with the USPTO. Of these, 4 registered, 6 abandoned, 3 cancelled.
What trademark classes does BIOVIGILANT SYSTEMS, INC. file in?
BIOVIGILANT SYSTEMS, INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 9 (Computers & Electronics), Class 41 (Education & Entertainment). Class 9 covers scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments.
What are BIOVIGILANT SYSTEMS, INC.'s most well-known trademarks?
BIOVIGILANT SYSTEMS, INC.'s registered trademark portfolio includes well-known marks such as IMD-A, BIOVIGILANT, and PHARMAMASTER. These are among 4 currently registered trademarks in the portfolio.
What is BIOVIGILANT SYSTEMS, INC.'s trademark registration success rate?
BIOVIGILANT SYSTEMS, INC. has a 31% trademark registration rate, with 4 out of 13 resolved applications resulting in successful registration. Currently, 0 applications are pending review.